Esophageal cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview[edit | edit source]

Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer.

Secondary Prevention[edit | edit source]

Secondary prevention can be effective in high risk groups with advanced dysplasia if they are treated (with monoclonal antibodies) early enough in the dysplastic phase before cancer occurs.^[1]

• A high risk group who frequently smoke and drink alcohol were identified in Hishun village, China.
• They were examined by esophageal exfoliative cytology.
• One third of the participants were found to have advanced esophageal dysplasia.
• They were placed on an antitumor B regimen for 3 years.
• Patients who were treated with monoclonal antibodies subsequently showed a reduction in the incidence of esophageal cancer by 53%.
• These results demonstrate the effectiveness of secondary prevention in the prevention of esophageal cancer.

References[edit | edit source]

Template:WikiDoc Sources